iBio, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
Mailing Address 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
Phone 302 355-0650
Fiscal Year End 0630
EIN 262797813
Financial Overview
FY2025
$21.32M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 6, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K September 5, 2025
- Advanced lung fibrosis drug to mid-stage trials
- Launched IBIO-600 and IBIO-610 programs
Insider Trading
BUY 3 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.